Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported Q2 2026 revenue of $23.0 million, down from $35.4 million a year earlier, while diluted EPS swung to a loss of $0.07 from profit of $0.02. For the three months ended June 30, gross margin fell to 57.9% and non-GAAP adjusted EBITDA turned negative. The lower revenue base and less favorable mix reduced gross profit faster than operating costs could adjust.

Core financial results

Revenue declined primarily because Xtant sold its non-core Coflex/CoFix assets and international hardware business in December 2025. The company also recorded no license revenue in the quarter, compared with $5.0 million a year earlier, following reimbursement changes that ended revenue from its Q-code and amniotic membrane agreements.

Gross margin contracted by 10.7 percentage points because the discontinued license revenue carried a high margin. Reduced production efficiency and higher excess and obsolete inventory charges added further pressure. Operating expenses increased because of a $5.0 million Dilon Technologies exclusivity fee, partly offset by lower general and administrative and sales and marketing expenses after the divestitures.

Business and portfolio performance

Product revenue was $23.031 million, down approximately 24.3% from $30.436 million. License revenue fell to zero from $4.975 million, accounting for a substantial part of the total revenue decline and having a disproportionate effect on gross margin because of its high-margin profile.

Xtant entered an exclusive U.S. distribution agreement with Dilon Technologies for HEMOBLAST Bellows, a hemostatic product used following certain surgical procedures. The company also hired approximately 20 members of Dilon’s U.S. sales team, who will support Xtant’s broader biologics portfolio.

The company separately launched Trivium Shaped, an extension of its demineralized bone matrix allograft line. Management said the Dilon agreement, additional commercial personnel, and Trivium product launch are intended to broaden the biologics portfolio and expand access to hospitals and surgeons.

Profitability, cash flow, and the balance sheet

The available cash-flow figures cover the first six months of 2026 rather than Q2 alone. During that period, Xtant used $9.422 million of operating cash, compared with generating $2.554 million in the first half of 2025. Working-capital movements included $3.591 million of cash absorbed by inventory and $2.076 million by accounts receivable.

As of June 30, cash and cash equivalents were $9.870 million, down from $17.053 million at the end of 2025. Inventory increased to $33.287 million from $30.263 million, consistent with the working-capital cash use and the quarter’s higher excess and obsolete inventory charges.

Total debt declined to $23.0 million from $25.4 million at year-end, reflecting a $3.8 million reduction in term-loan principal, partly offset by $1.1 million of net revolving-credit borrowings during the first half. Revolver availability fell to $0.7 million from $3.8 million. Management stated that current cash and credit availability should fund operations as presently planned for at least the next 12 months.

The Dilon fee amplified the loss, but underlying profitability also deteriorated

The $5.0 million Dilon-related write-off was a major reason operating expenses increased and GAAP operating results moved sharply into the red. However, it does not fully explain the profitability reversal: Xtant excludes that charge when calculating adjusted EBITDA, yet adjusted EBITDA still fell from positive $6.904 million to a loss of $2.678 million.

That non-GAAP deterioration indicates that the weaker result extended beyond the one-time charge. Total revenue fell by $12.380 million, including the loss of $4.975 million in high-margin license revenue, while lower production efficiency and inventory charges further reduced gross profitability. The resulting $10.954 million decline in gross profit left the company with less capacity to absorb its remaining operating cost base.

Financial guidance

Xtant reduced its full-year 2026 revenue outlook after biologics revenue came in below management’s expectations in Q2 and its amnio product line continued to face headwinds tied to the advanced wound care market. The midpoint declined by $2 million, or approximately 1.9%.

Recent insider transactions

The supplied six-month insider summary showed no insider purchases or sales and listed total insider holdings of 19.41 million shares. In the detailed two-year records, the most recent entries consisted mainly of stock awards; these grants should not be treated as open-market purchases.

Risks investors should monitor

• Biologics and reimbursement pressure: Weaker Q2 biologics revenue and continuing amnio headwinds prompted the guidance reduction. Further pressure could make the revised revenue range harder to achieve.
• Sustained margin weakness: The loss of high-margin license revenue, reduced production efficiency, and excess inventory charges could continue to weigh on gross margin even after year-over-year comparisons begin reflecting the divested businesses.
• Cash consumption and limited revolver availability: First-half operating cash use reached $9.4 million, while cash fell to $9.9 million and unused revolving-credit capacity was only $0.7 million at quarter-end.
• Execution of the Dilon agreement: Xtant must integrate the additional sales personnel and commercialize HEMOBLAST effectively. The agreement also carries termination and supply risks, including uncertainty over recovering the $5.0 million exclusivity payment if the arrangement ends.

Summary

Xtant Medical’s Q2 2026 results reflected a materially smaller revenue base following asset sales and the end of high-margin license income. Those changes, combined with production inefficiencies, inventory charges, and the Dilon fee, pushed both GAAP earnings and adjusted EBITDA into losses. The main issues to watch are whether the expanded biologics portfolio can restore product growth, whether gross margin stabilizes, and whether the company can limit cash consumption while delivering its reduced full-year revenue guidance.

Find out more